-

12:06:07 PM

VIRI Stock News

VIRI - Virios Therapeutics Inc

03/14/23 7:05 AM

Nasdaq : VIRI

earningslow float

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results

RHEA-AI

neutral

03/07/23 7:05 AM

Nasdaq : VIRI

conferencesearningslow float

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), announced today that it will report fourth quarter

RHEA-AI

neutral

02/13/23 7:05 AM

Nasdaq : VIRI

covid-19low float

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that it expects top-line

RHEA-AI

neutral

01/05/23 7:00 AM

Nasdaq : VIRI

clinical triallow float

Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that its end-of-Phase 2

RHEA-AI

neutral

11/29/22 7:05 AM

Nasdaq : VIRI

conferenceslow float

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking...

RHEA-AI

neutral

11/14/22 7:05 AM

Nasdaq : VIRI

earningslow float

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia, today announced financial results for the third quarter ended September 30, 2022, as well as plans to advance development of its lead antiviral development...

RHEA-AI

neutral

11/03/22 7:05 AM

Nasdaq : VIRI

conferencesearningslow float

Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets.

RHEA-AI

neutral

09/22/22 4:15 PM

Nasdaq : VIRI

offeringlow float

Virios Therapeutics, Inc. Announces Closing of Public Offering

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of...

RHEA-AI

neutral

09/19/22 10:04 PM

Nasdaq : VIRI

offeringlow float

Virios Therapeutics, Inc. Announces Pricing of Public Offering

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for...

RHEA-AI

neutral

09/19/22 4:05 PM

Nasdaq : VIRI

offeringlow float

Virios Therapeutics, Inc. Announces Proposed Public Offering

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. ThinkEquity is acting as sole book-running...

RHEA-AI

neutral

1 2 3 4 5 6 Next

VIRI Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.virios.com
Security nameVirios Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees5

About Virios Therapeutics Inc

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ('FM'). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 ('HSV-1') has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease ('IBS'), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor. Our lead development candidate ('IMC-1'), is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.